Literature DB >> 7666518

High-level hepatitis B virus replication in transgenic mice.

L G Guidotti1, B Matzke, H Schaller, F V Chisari.   

Abstract

Hepatitis B virus (HBV) transgenic mice whose hepatocytes replicate the virus at levels comparable to that in the infected livers of patients with chronic hepatitis have been produced, without any evidence of cytopathology. High-level viral gene expression was obtained in the liver and kidney tissues in three independent lineages. These animals were produced with a terminally redundant viral DNA construct (HBV 1.3) that starts just upstream of HBV enhancer I, extends completely around the circular viral genome, and ends just downstream of the unique polyadenylation site in HBV. In these animals, the viral mRNA is more abundant in centrilobular hepatocytes than elsewhere in the hepatic lobule. High-level viral DNA replication occurs inside viral nucleocapsid particles that preferentially form in the cytoplasm of these centrilobular hepatocytes, suggesting that an expression threshold must be reached for nucleocapsid assembly and viral replication to occur. Despite the restricted distribution of the viral replication machinery in centrilobular cytoplasmic nucleocapsids, nucleocapsid particles are detectable in the vast majority of hepatocyte nuclei throughout the hepatic lobule. The intranuclear nucleocapsid particles are empty, however, suggesting that viral nucleocapsid particle assembly occurs independently in the nucleus and the cytoplasm of the hepatocyte and implying that cytoplasmic nucleocapsid particles do not transport the viral genome across the nuclear membrane into the nucleus during the viral life cycle. This model creates the opportunity to examine the influence of viral and host factors on HBV pathogenesis and replication and to assess the antiviral potential of pharmacological agents and physiological processes, including the immune response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666518      PMCID: PMC189513     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  HBx gene of hepatitis B virus induces liver cancer in transgenic mice.

Authors:  C M Kim; K Koike; I Saito; T Miyamura; G Jay
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

2.  Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity.

Authors:  G Radziwill; W Tucker; H Schaller
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

3.  Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification.

Authors:  J Summers; P M Smith; A L Horwich
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

Review 4.  Chronic type B hepatitis and the "healthy" HBsAg carrier state.

Authors:  J H Hoofnagle; D A Shafritz; H Popper
Journal:  Hepatology       Date:  1987 Jul-Aug       Impact factor: 17.425

5.  Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

Authors:  D R Milich; J E Jones; J L Hughes; J Price; A K Raney; A McLachlan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice.

Authors:  T H Lee; M J Finegold; R F Shen; J L DeMayo; S L Woo; J S Butel
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Replication and gene expression of hepatitis B virus in a transgenic mouse that contains the complete viral genome.

Authors:  H Farza; M Hadchouel; J Scotto; P Tiollais; C Babinet; C Pourcel
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

8.  Detection of hepatitis B virus X gene protein and antibody in type B chronic liver disease.

Authors:  K Katayama; N Hayashi; Y Sasaki; A Kasahara; K Ueda; H Fusamoto; N Sato; O Chisaka; K Matsubara; T Kamada
Journal:  Gastroenterology       Date:  1989-10       Impact factor: 22.682

9.  Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines.

Authors:  S Guilhot; P Fowler; G Portillo; R F Margolskee; C Ferrari; A Bertoletti; F V Chisari
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA.

Authors:  M Junker-Niepmann; R Bartenschlager; H Schaller
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

View more
  278 in total

1.  Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions.

Authors:  C R Madden; M J Finegold; B L Slagle
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

3.  Transcriptional repression of human hepatitis B virus genes by a bZIP family member, E4BP4.

Authors:  C K Lai; L P Ting
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

4.  Establishment of transgenic mouse harboring hepatitis B virus (adr subtype) genomes.

Authors:  Y P Hu; W J Hu; W C Zheng; J X Li; D S Dai; X M Wang; S Z Zhang; H Y Yu; W Sun; G R Hao
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

5.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 6.  Immune escape by hepatitis B viruses.

Authors:  U Protzer; H Schaller
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

7.  Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.

Authors:  Kazuhiro Kakimi; Masanori Isogawa; JoSan Chung; Alessandro Sette; Francis V Chisari
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus.

Authors:  Sílvia Vilarinho; Kouetsu Ogasawara; Stephen Nishimura; Lewis L Lanier; Jody L Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-08       Impact factor: 11.205

9.  Limited effects of fasting on hepatitis B virus (HBV) biosynthesis in HBV transgenic mice.

Authors:  Lie Li; Claudia E Oropeza; Klaus H Kaestner; Alan McLachlan
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

10.  Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver.

Authors:  S F Wieland; S Asabe; R E Engle; R H Purcell; F V Chisari
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.